The prevalence of long COVID is more than a hundred times greater than the definition of a rare disease – yet there are no specific health services or support.

@1goodtern: Ten ways covid denialists use exactly the same playbook as climate change denialists to justify doing nothing:

The JN.1 variant has become dominant in Australia and around the world, causing large waves of infections. Here’s what we know about it so far – and why it’s so important.

This link will take you to a page that’s not on LinkedIn

A clinical trial shows a non-invasive magnetic headset improves long COVID brain fog and emotional well-being, with gains lasting weeks post-treatment.

After a life-threatening infection, the Australian singer-songwriter has rebuilt her relationship with music – and her third album ‘sounds nothing like the last’

The patient had been living in DR Congo, where more than 4,000 people have died from the disease this year.

Modified medication targets the cells implicated in the condition’s tell-tale lesions.

NEW WHO ESTIMATES: NCDs AND MENTAL HEALTH CONDITIONS CONTINUE TO RISE New estimates from WHO show major shifts in global health trends. While global life expectancy reached 73.3 years in 2023, on pa...

In this exploratory randomized trial, the monoclonal antibody AER002 was safe but did not improve clinical or biomarker outcomes in Long COVID. Post-hoc findings suggest baseline antibody levels and d...

YouTube video by Long Covid Kids

Dr Swasti Raychaudhuri, who led the research, noted that although cells possess protective mechanisms, biochemical reactions can undergo changes depending on the circumstances.

The National Epidemiology Center reports a sharp rise in COVID-19 incidence, prompting a massive increase in diagnostic test supplies.

Changes in guidance and science seem to have little impact on millions of devastated lives. It’s a social crisis playing out behind closed doors, says Guardian columnist George Monbiot

After an extensive review process, scientists have selected dozens of biomarkers to study as part of the RECOVER-TLC clinical trials.